Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY007 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06279611Phase 1Recruiting
- Sponsor
- Shanghai Longyao Biotechnology Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY007 in B-cell non-Hodgkin lymphoma, sponsored by Shanghai Longyao Biotechnology Co., Ltd. Primary endpoints: Maximum Tolerated Dose or Clinically Recommended Dose at 2 years, Dose Limiting Toxicity at 2 years and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
LY007
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06279611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279611.